Arrhythmia Disorders News

In patients with nonischemic cardiomyopathy, women had lower rates of ventricular arrhythmias and death than men, especially if they had a cardiac resynchronization therapy defibrillator, according to the results of the BIO-LIBRA study.

In patients with atrial fibrillation, pulsed field ablation was associated with reduced atrial arrhythmia burden and improved quality of life, according to new data from the PULSED AF trial.

Extraction of a subcutaneous implantable cardioverter defibrillator was safe and feasible and produced no complications, according to registry data presented at Heart Rhythm 2023.

Among patients with atrial fibrillation who chose to undergo catheter ablation, those who lost at least 3% of body weight before the procedure were more likely to be free from AF at 6 months, according to early results of the LEAF trial.

In a comparison of two cohorts, the rate of stroke was higher in East Asian adults than in white adults, though atrial fibrillation influenced the stroke rate equally in both groups, researchers reported at Heart Rhythm 2023.

Abbott announced the FDA approved its sensor-enabled ablation catheter for treatment of atrial fibrillation.

Abbott announced the FDA cleared its insertable cardiac monitor for diagnosis and evaluation of irregular heartbeats.

Atrial fibrillation is common, affecting approximately 5.2 million patients in 2010 in the United States, and this is projected to increase to 12.1 million in 2030.

Medtronic announced its artificial intelligence algorithm technology received market clearance from the FDA to apply the algorithms to its previous-generation insertable wireless cardiac monitor via cloud-based updates.

Bayer announced the FDA has granted fast track designation for asundexian — a once-daily oral factor XIa inhibitor — for the prevention of stroke and systemic embolism in patients with atrial fibrillation.